• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Merit Medical Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    5/21/24 4:52:24 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email
    0000856982false--12-31MERIT MEDICAL SYSTEMS INC00008569822024-05-152024-05-15

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): May 15, 2024

    ​

    Graphic

    ​

    Merit Medical Systems, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Utah

        

    0-18592

        

    87-0447695

    (State or other jurisdiction of

    ​

    (Commission

    ​

    (I.R.S. Employer

    incorporation or organization)

    ​

    File Number)

    ​

    Identification No.)

    ​

    ​

    ​

    ​

    1600 West Merit Parkway

        

    ​

    South Jordan, Utah

    ​

    84095

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (801) 253-1600

    (Registrant's telephone number, including area code)

    ​

    N/A

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, no par value

    ​

    MMSI

    ​

    NASDAQ Global Select Market System

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company        ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 1.01.  Entry into a Material Definitive Agreement.

    ​

    On May 15, 2024, Merit Medical Systems, Inc. (“Merit”) entered into an indemnification agreement (the “Indemnification Agreement”) with Silvia M. Perez in connection with her election as a director of Merit.  The Indemnification Agreement is in substantially the same form as the indemnification agreements entered into between Merit and each of its existing directors and previously filed with the U.S. Securities and Exchange Commission.    

    ​

    In general, the Indemnification Agreement provides that Merit will indemnify Ms. Perez, to the fullest extent permitted by applicable law, against all expenses, and liabilities of any type whatsoever actually and reasonably incurred in connection with her service to, or at the request of, Merit. This indemnification is only available if she acted in good faith and in a manner she reasonably believed to be in or not opposed to the best interests of Merit, and with respect to any criminal action or proceeding, she had no reasonable cause to believe her conduct was unlawful.

    ​

    In addition and subject to certain limitations, the Indemnification Agreement provides for the advancement of expenses incurred by Ms. Perez in connection with any proceeding covered by the Indemnification Agreement. In order to obtain such advancement, she must provide Merit with an undertaking to repay all amounts if it is ultimately determined that she is not entitled to indemnification for such expenses.

    ​

    The Indemnification Agreement does not exclude any other rights to indemnification or advancement of expenses to which Ms. Perez may be entitled, including any rights arising under applicable law, Merit’s articles of incorporation and bylaws, any other agreement, a vote of shareholders or resolution of directors, or otherwise.

    ​

    The foregoing summary is qualified in its entirety by reference to the Indemnification Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated in this Item 1.01 by reference.

    ​

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    ​

    Executive Compensation Arrangements

    ​

    At Merit’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) held on May 15, 2024, Merit’s shareholders approved an amendment to Merit’s 2018 Long-Term Incentive Plan (the “Incentive Plan”), to increase the number of authorized shares reserved for issuance under the Incentive Plan by 3,000,000 shares. A description of the Incentive Plan, the amendment and related matters is set forth in Merit’s definitive proxy statement on Form DEF 14A filed with the U.S. Securities and Exchange Commission on April 2, 2024 (the “Proxy Statement”) and is incorporated herein by reference. Merit’s Board of Directors (the “Board”) previously approved the amendment to the Incentive Plan, subject to receipt of shareholder approval at the Annual Meeting.

    ​

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    ​

    On May 16, 2024, Merit’s Board amended and restated Merit’s Third Amended and Restated Bylaws (as so amended and restated, the “Fourth Amended and Restated Bylaws”), effective immediately. The amendments delineate the rights and responsibilities of the roles of the Chief Executive Officer and President. Previously, Fred P. Lampropoulos was acting as both President and Chief Executive Officer; however, the Board appointed Joseph C. Wright as Merit’s President on May 15, 2024, and Mr. Lampropoulos resigned from that position. Mr. Lampropoulos continues to serve as Merit’s Chief Executive Officer. The amendments principally:

    ​
    ​

    (i)Revised Article II Section 2 to allow the Chief Executive Officer rather than the President to call special meetings of the shareholders;
    (ii)Revised Article III Section 4 to allow the Chief Executive Officer rather than the President to call special meetings of the Board;

    2

    ​

    (iii)Revised Article IV Section 1 to provide that the officers of Merit shall include a Chief Executive Officer;
    (iv)Revised Article IV Section 5 to specify that the Chief Executive Officer rather than the President shall, among other things, generally supervise and control Merit’s business and affairs and preside at all meetings of the shareholders and the Board;
    (v)Added a new Section 6 to Article IV stating, among other things, that the President, subject to the direction and supervision of the Chief Executive Officer, shall (i) be responsible for Merit’s operational affairs; and (ii) assist the Chief Executive Officer and perform such duties as may be assigned by the Chief Executive Officer and that the President shall, at the request of the Chief Executive Officer, or in the absence, inability or refusal to act of the Chief Executive Officer, perform the duties of the Chief Executive Officer; and
    (vi)Revised Article IV Sections 7, 8 and 9 to specify that the Vice-President, Secretary, and Treasurer shall perform the duties assigned by the Chief Executive Officer rather than the President.

    ​

    The foregoing summary is qualified in its entirety by reference to the Fourth Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated in this Item 5.03 by reference.

    ​

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    ​

    At the Annual Meeting, Merit’s shareholders voted on the following proposals:

    ​

    (1)Election of three nominees, each to serve as a director of Merit until the 2027 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified;
    (2)Non-binding advisory proposal to approve the compensation of Merit’s named executive officers, otherwise known as a “say-on-pay” vote;
    (3)Approval of an amendment to increase the number of shares authorized for issuance under the Incentive Plan by 3,000,000 shares; and
    (4)Ratification of the appointment of Deloitte & Touche LLP as Merit’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

    ​

    ​

    ​

    ​

    ​

    A total of 58,064,556 shares of Merit’s common stock were entitled to vote at the Annual Meeting as of March 18, 2024, the record date for the Annual Meeting, of which 53,684,559 shares were represented in person or by proxy at the Annual Meeting.

    ​

    The voting results with respect to each of the proposals are discussed further below.

    ​

    Proposal 1 - Election of Directors

    ​

    The votes cast for or withheld for each director nominee were as follows:

    ​

    Director Nominee

     

    For

    Against

    Abstain

    Broker Non-Votes

    Fred P. Lampropoulos

     

    50,241,576

    1,594,638

    19,403

    1,828,942

    Stephen C. Evans

     

    50,385,611

    1,444,499

    25,507

    1,828,942

    Silvia M. Perez

     

    51,069,864

    707,106

    78,647

    1,828,942

    ​

    Accordingly, each of the three nominees listed above was elected to serve as a director of Merit until the 2027 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified.

    ​

    Proposal 2 - Advisory Vote on Executive Compensation

    ​

    The results of the voting on a non-binding advisory proposal to approve the compensation of Merit’s named executive officers were as follows:

    ​

    3

    ​

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    49,962,560

    1,838,121

    54,936

    1,828,942

    ​

    Accordingly, a majority of votes cast with respect to the advisory “say-on-pay” proposal were “for” approval of the compensation of Merit’s named executive officers, as disclosed in the Proxy Statement.

    ​

    Proposal 3 – Approval of an amendment to increase the number of shares authorized for issuance under the Incentive Plan by 3,000,000 shares

    ​

    The results of the voting on the increase of the number of shares authorized under the Incentive Plan were as follows:

    ​

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    49,916,011

    1,844,571

    95,035

    1,828,942

    ​

    Accordingly, a majority of votes cast with respect to the amendment to increase the number of shares authorized under the Incentive Plan were “for” approval.

    ​

    Proposal 4 - Ratification of Appointment of Independent Registered Public Accounting Firm

    ​

    The voting results with respect to the proposal to ratify the appointment of Deloitte & Touche LLP to serve as Merit’s independent registered public accounting firm for the fiscal year ending December 31, 2024 were as follows:

    ​

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    51,765,374

    1,891,519

    27,666

    0

    ​

    Accordingly, Merit’s shareholders ratified the appointment of Deloitte and Touche LLP to serve as Merit’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

    ​

    No other matters were submitted to a vote of shareholders at the Annual Meeting.

    ​

    Item 8.01. Other Events.

    ​

    On May 16, 2024, Merit issued a press release announcing the election of Ms. Perez as a Director.  A copy of that press release is attached hereto as Exhibit 99.1. The information contained in Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

    ​

    Item 9.01.  Financial Statements and Exhibits.

    ​

    (d)            Exhibits

    ​

    ​

    ​

    EXHIBIT NUMBER

     

    DESCRIPTION

    3.1

    ​

    Fourth Amended and Restated Bylaws of Merit Medical Systems, Inc. dated May 16, 2024

    10.1

    ​

    Indemnification Agreement dated May 15, 2024 between Merit Medical Systems, Inc. and Silvia M. Perez

    99.1

    ​

    Press Release, dated May 16, 2024, entitled “Merit Medical Shareholders Elect Silvia M. Perez as New Director”

    104

    ​

    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

    ​

    4

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    MERIT MEDICAL SYSTEMS, INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 21, 2024

    By:

    /s/ Brian G. Lloyd

    ​

    ​

    Brian G. Lloyd

    ​

    ​

    Chief Legal Officer and Corporate Secretary

    ​

    ​

    ​

    5

    Get the next $MMSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    2/6/2026$107.00Buy
    BTIG Research
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MMSI
    SEC Filings

    View All

    Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    1/8/26 4:33:36 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    11/13/25 5:14:59 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    11/3/25 5:24:14 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

    SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit's Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She previously served as the Chair of Merit's Governance and Sustainability Committee. Dr. Millner currently serves as a member of the Utah State Senate, to which she was elected in 2015. She served as the President of Weber State University from 2002 through 2012

    1/8/26 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical to Participate at the J.P. Morgan Healthcare Conference

    SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit Healthcare Conference. Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, January 13th at 4:30 pm Pacific Time / 7:30 pm Eastern Time. Presentation materials for the conference will be posted to Merit's investor relations websi

    12/23/25 9:00:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis

    SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services ("CMS") has notified Merit that its application for Transitional Pass-Through ("TPT") incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis ("CIE") procedures in the outpatient and ambulatory surgery center ("ASC") settings requires further consideration prior to CMS making a final decision. CMS notified Merit that it has deferred Merit's application for the WRAPSODY® CIE to the Calendar Year 2027 Outpatient Prospective Payment System rule, making January 1, 2027, the ear

    11/13/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Merit Medical with a new price target

    BTIG Research initiated coverage of Merit Medical with a rating of Buy and set a new price target of $107.00

    2/6/26 7:51:56 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Merit Medical with a new price target

    Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

    3/28/25 8:20:21 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

    12/11/24 7:56:29 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Peterson Neil W. exercised 5,000 shares at a strike of $54.40 and sold $450,000 worth of shares (5,000 units at $90.00) (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    1/8/26 12:57:30 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Executive Chairman Lampropoulos Fred P. sold $880,377 worth of shares (10,000 units at $88.04), decreasing direct ownership by 0.97% to 1,019,955 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    11/26/25 3:22:04 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Executive Chairman Lampropoulos Fred P. sold $2,182,750 worth of shares (25,000 units at $87.31), decreasing direct ownership by 2% to 1,029,955 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    11/24/25 6:00:32 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Leadership Updates

    Live Leadership Updates

    View All

    Merit Medical Announces Resignation of President, Joseph Wright

    SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

    12/16/24 4:00:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Shareholders Elect Silvia M. Perez as New Director

    SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

    5/16/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Executive Leadership Team Update

    Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

    5/15/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Financials

    Live finance-specific insights

    View All

    Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

    SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit's Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She previously served as the Chair of Merit's Governance and Sustainability Committee. Dr. Millner currently serves as a member of the Utah State Senate, to which she was elected in 2015. She served as the President of Weber State University from 2002 through 2012

    1/8/26 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance

    Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quarter compared with the third quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Const

    10/30/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025

    SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

    10/3/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    11/14/24 11:05:03 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/13/24 5:09:38 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/12/24 5:32:43 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care